MTOR and diffuse large B-cell lymphoma: Lastly, AKT S473D expression completely abrogated the synergy between AKT inhibitors and BCL-2 inhibitors in DLBCL cells, and partially reversed the sensitization by dual PI3K/mTOR inhibitors (Figure 6C).